193 related articles for article (PubMed ID: 36969380)
1. Hyperlipidaemia elicits an atypical, T helper 1-like CD4
van Os BW; Vos WG; Bosmans LA; van Tiel CM; Lith SC; den Toom MS; Beckers L; Levels JHM; van Wouw SAE; Zelcer N; Zaal EA; Berkers CR; van der Lest CHA; Helms JB; Weber C; Atzler D; de Winther MPJ; Baardman J; Lutgens E
Eur Heart J Open; 2023 Mar; 3(2):oead013. PubMed ID: 36969380
[TBL] [Abstract][Full Text] [Related]
2. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
3. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
[TBL] [Abstract][Full Text] [Related]
4. Postprandial lipoproteins and the molecular regulation of vascular homeostasis.
Botham KM; Wheeler-Jones CP
Prog Lipid Res; 2013 Oct; 52(4):446-64. PubMed ID: 23774609
[TBL] [Abstract][Full Text] [Related]
5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
6. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
[TBL] [Abstract][Full Text] [Related]
7. Autoreactive Tbet-positive CD4 T cells develop independent of classic Th1 cytokine signaling during experimental autoimmune encephalomyelitis.
Yeh WI; McWilliams IL; Harrington LE
J Immunol; 2011 Nov; 187(10):4998-5006. PubMed ID: 21984703
[TBL] [Abstract][Full Text] [Related]
8. Specific Loss of ABCA1 (ATP-Binding Cassette Transporter A1) Suppresses TCR (T-Cell Receptor) Signaling and Provides Protection Against Atherosclerosis.
Zhao Y; Zhang L; Liu L; Zhou X; Ding F; Yang Y; Du S; Wang H; Van Eck M; Wang J
Arterioscler Thromb Vasc Biol; 2022 Dec; 42(12):e311-e326. PubMed ID: 36252122
[TBL] [Abstract][Full Text] [Related]
9. Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-gamma.
Whitman SC; Argmann CA; Sawyez CG; Miller DB; Hegele RA; Huff MW
J Lipid Res; 1999 Jun; 40(6):1017-28. PubMed ID: 10357833
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.
Huang Y; Ji ZS; Brecht WJ; Rall SC; Taylor JM; Mahley RW
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2952-9. PubMed ID: 10591675
[TBL] [Abstract][Full Text] [Related]
11. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice.
Draijer R; Volger OL; Dahlmans VE; de Wit EC; Havekes LM; Princen HM
Biochem Pharmacol; 2002 May; 63(9):1755-61. PubMed ID: 12007578
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
Huang Y; Liu XQ; Rall SC; Mahley RW
J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
[TBL] [Abstract][Full Text] [Related]
13. Very-low-density lipoprotein-induced triglyceride accumulation in human mesangial cells is mainly mediated by lipoprotein lipase.
Li J; Li H; Wen YB; Li XW
Nephron Physiol; 2008; 110(1):p1-10. PubMed ID: 18698144
[TBL] [Abstract][Full Text] [Related]
14. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us G; Mushtaq S
Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
[TBL] [Abstract][Full Text] [Related]
15. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
Wang Y; Tang W; Yang P; Shin H; Li Q
Biochem Biophys Res Commun; 2018 May; 499(3):626-633. PubMed ID: 29601818
[TBL] [Abstract][Full Text] [Related]
16. Absence of gravin-mediated signaling inhibits development of high-fat diet-induced hyperlipidemia and atherosclerosis.
Fan Q; Yin X; Rababa'h A; Diaz Diaz A; Wijaya CS; Singh S; Suryavanshi SV; Vo HH; Saeed M; Zhang Y; McConnell BK
Am J Physiol Heart Circ Physiol; 2019 Oct; 317(4):H793-H810. PubMed ID: 31441691
[TBL] [Abstract][Full Text] [Related]
17. Differentiating hyperlipidaemia associated with antiretroviral therapy.
Mauss S; Stechel J; Willers R; Schmutz G; Berger F; Richter WO
AIDS; 2003 Jan; 17(2):189-94. PubMed ID: 12545078
[TBL] [Abstract][Full Text] [Related]
18. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation.
Takahashi S
J Atheroscler Thromb; 2017 Jun; 24(6):552-559. PubMed ID: 28428482
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
